{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:42Z","timestamp":1790192802308,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinisch Wissenschaftlicher Fonds des B\u00fcrgermeisters der Stadt Wien","award":["17001"],"award-info":[{"award-number":["17001"]}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Practice patterns of eculizumab use are not well described. We examined indications for, and outcomes of, eculizumab therapy in a tertiary care nephrology center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the \u201cVienna TMA cohort\u201d and the hospital pharmacy database at the Medical University of Vienna to identify patients that received eculizumab treatment between 2012 and 2019. We describe clinical characteristics, details of eculizumab use, and outcomes of patients with complement gene-variant mediated TMA (cTMA), secondary TMA (sTMA) and C3 glomerulopathy (C3G).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of December 2019, 23 patients received complement blockade at the Division of Nephrology and Dialysis: 15 patients were diagnosed with cTMA, 6 patients with sTMA and 2 patients with C3G. Causes of sTMA were bone marrow transplantation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), malignant hypertension, malignant tumor, systemic lupus erythematosus, antiphospholipid syndrome and lung transplantation (each\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Across all indications, patients had a median age of 31 and were predominantly female (78%) and the median duration of treatment was 227\u00a0days. Hematological recovery was seen in most patients, while renal response was best in patients with cTMA. Adverse events were recorded in 26%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, eculizumab is the treatment of choice for cTMA patients that do not respond to plasma therapy. In patients with sTMA and C3G, the response rates to therapy are much lower and therefore, the decision to start therapy needs to be considered carefully.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-021-00981-8","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T10:07:09Z","timestamp":1613729229000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-8010","authenticated-orcid":false,"given":"Christof","family":"Aigner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3422-2245","authenticated-orcid":false,"given":"Martina","family":"Gaggl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunar","family":"Stemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-1275","authenticated-orcid":false,"given":"Michael","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-912X","authenticated-orcid":false,"given":"Georg","family":"B\u00f6hmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-543X","authenticated-orcid":false,"given":"Renate","family":"Kain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-7982","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-4473","authenticated-orcid":false,"given":"N\u00f3ra","family":"Garam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-9852","authenticated-orcid":false,"given":"Dorottya","family":"Csuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-118X","authenticated-orcid":false,"given":"Raute","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9322-0509","authenticated-orcid":false,"given":"Leah Charlotte","family":"Piggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-1007","authenticated-orcid":false,"given":"Natalja","family":"Haninger-Vacariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-0044","authenticated-orcid":false,"given":"Alice","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-9921","authenticated-orcid":false,"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"981_CR1","unstructured":"Soliris (2020) European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed 1 May 2020"},{"issue":"2","key":"981_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1681\/ASN.2019050515","volume":"31","author":"PF Zipfel","year":"2020","unstructured":"Zipfel PF, Wiech T, Stea ED, Skerka C (2020) CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol 31(2):241\u2013256. https:\/\/doi.org\/10.1681\/ASN.2019050515","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"981_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654\u2013666. https:\/\/doi.org\/10.1056\/NEJMra1312353","journal-title":"N Engl J Med"},{"issue":"9","key":"981_CR4","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.transproceed.2016.04.005","volume":"48","author":"J Merola","year":"2016","unstructured":"Merola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, Mulligan DC, Asch W, Formica R, Kashgarian M, Kulkarni S (2016) Belatacept and eculizumab for treatment of calcineurin inhibitor-induced thrombotic microangiopathy after kidney transplantation: case report. Transplant Proc 48(9):3106\u20133108. https:\/\/doi.org\/10.1016\/j.transproceed.2016.04.005","journal-title":"Transplant Proc"},{"issue":"5","key":"981_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D\u2019Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7(5):748\u2013756. https:\/\/doi.org\/10.2215\/CJN.12901211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"981_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","volume":"130","author":"SA Merrill","year":"2017","unstructured":"Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA (2017) Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 130(3):368\u2013372. https:\/\/doi.org\/10.1182\/blood-2017-02-770214","journal-title":"Blood"},{"issue":"4","key":"981_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64(4):633\u2013637. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"981_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1681\/ASN.2016090995","volume":"29","author":"M Gaggl","year":"2018","unstructured":"Gaggl M, Aigner C, Csuka D, Szilagyi A, Proh\u00e1szka Z, Kain R, Haninger N, Knechtelsdorfer M, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A (2018) Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol 29(3):1020\u20131029. https:\/\/doi.org\/10.1681\/ASN.2016090995","journal-title":"J Am Soc Nephrol"},{"key":"981_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejim.2019.11.007","volume":"73","author":"C Aigner","year":"2020","unstructured":"Aigner C, B\u00f6hmig GA, Eskandary F, Herkner H, Proh\u00e1szka Z, Csuka D, Kain R, Gaggl M, Sunder-Plassmann R, M\u00fcller-Sacherer T, Oszwald A, Fischer G, Schmidt A, Sunder-Plassmann G (2020) Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients. Eur J Intern Med 73:51\u201358. https:\/\/doi.org\/10.1016\/j.ejim.2019.11.007","journal-title":"Eur J Intern Med"},{"key":"981_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040964","author":"C Aigner","year":"2020","unstructured":"Aigner C, Gaggl M, Kain R, Proh\u00e1szka Z, Garam N, Csuka D, Sunder-Plassmann R, Piggott LC, Haninger-Vacariu N, Schmidt A, Sunder-Plassmann G (2020) Sex differences in clinical presentation and outcomes among patients with complement-gene-variant-mediated thrombotic microangiopathy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9040964","journal-title":"J Clin Med"},{"issue":"2","key":"981_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.xkme.2019.12.004","volume":"2","author":"N Haninger-Vacariu","year":"2020","unstructured":"Haninger-Vacariu N, Aigner C, Kain R, Proh\u00e1szka Z, Gaggl M, B\u00f6hmig GA, Piggott LC, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A (2020) Successful pregnancies during eculizumab therapy in two patients with complement-mediated thrombotic microangiopathy. Kidney Medicine 2(2):213\u2013217. https:\/\/doi.org\/10.1016\/j.xkme.2019.12.004","journal-title":"Kidney Medicine"},{"key":"981_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa113","author":"N Haninger-Vacariu","year":"2020","unstructured":"Haninger-Vacariu N, Aigner C, Gaggl M, Kain R, Proh\u00e1szka Z, B\u00f6hmig G, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A (2020) Pregnancies in kidney transplant recipients with complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfaa113","journal-title":"Clin Kidney J"},{"issue":"11","key":"981_CR13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","volume":"221","author":"Z Proh\u00e1szka","year":"2016","unstructured":"Proh\u00e1szka Z, Nilsson B, Frazer-Abel A, Kirschfink M (2016) Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology 221(11):1247\u20131258. https:\/\/doi.org\/10.1016\/j.imbio.2016.06.008","journal-title":"Immunobiology"},{"issue":"4","key":"981_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ndt\/gfx196","volume":"33","author":"KL Wijnsma","year":"2017","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar N, Wetzels JFM (2017) Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 33(4):635\u2013645. https:\/\/doi.org\/10.1093\/ndt\/gfx196","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"981_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","volume":"63","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Chatelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Fremeaux-Bacchi V (2014) Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 63(1):40\u201348. https:\/\/doi.org\/10.1053\/j.ajkd.2013.07.011","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"981_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Merieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM (2019) Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol 14(4):557\u2013566. https:\/\/doi.org\/10.2215\/CJN.11470918","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"981_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13127","volume":"101","author":"J Rudoni","year":"2018","unstructured":"Rudoni J, Jan A, Hosing C, Aung F, Yeh J (2018) Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol 101(3):389\u2013398. https:\/\/doi.org\/10.1111\/ejh.13127","journal-title":"Eur J Haematol"},{"issue":"9","key":"981_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","volume":"99","author":"FS de Fontbrune","year":"2015","unstructured":"de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O\u2019Meara A, Fremeaux-Bacchi V, Veyradier A, Socie G, Coppo P, de Latour RP (2015) Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99(9):1953\u20131959. https:\/\/doi.org\/10.1097\/TP.0000000000000601","journal-title":"Transplantation"},{"issue":"13","key":"981_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM (2020) Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135(13):1049\u20131057. https:\/\/doi.org\/10.1182\/blood.2019004218","journal-title":"Blood"},{"issue":"9","key":"981_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2016.87","volume":"51","author":"S Vasu","year":"2016","unstructured":"Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S (2016) Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 51(9):1241\u20131244. https:\/\/doi.org\/10.1038\/bmt.2016.87","journal-title":"Bone Marrow Transplant"},{"key":"981_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15082","author":"S Chaturvedi","year":"2020","unstructured":"Chaturvedi S, Braunstein EM, Brodsky RA (2020) Antiphospholipid syndrome: complement activation, complement gene mutations and therapeutic implications. J Thromb Haemost. https:\/\/doi.org\/10.1111\/jth.15082","journal-title":"J Thromb Haemost"},{"issue":"1","key":"981_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","volume":"72","author":"M Le Quintrec","year":"2018","unstructured":"Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Fremeaux-Bacchi V, Fakhouri F (2018) Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72(1):84\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"981_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","volume":"73","author":"R Regunathan-Shenk","year":"2019","unstructured":"Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS (2019) Kidney transplantation in C3 glomerulopathy: a case series. Am J Kidney Dis 73(3):316\u2013323. https:\/\/doi.org\/10.1053\/j.ajkd.2018.09.002","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"981_CR24","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3201\/eid2408.180228","volume":"24","author":"D Nolfi-Donegan","year":"2018","unstructured":"Nolfi-Donegan D, Konar M, Vianzon V, MacNeil J, Cooper J, Lurie P, Sedivy J, Wang X, Granoff DM, McNamara L (2018) Fatal nongroupable neisseria meningitidis disease in vaccinated patient receiving eculizumab. Emerg Infect Dis 24(8):1561\u20131564. https:\/\/doi.org\/10.3201\/eid2408.180228","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"981_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Socie","year":"2019","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185(2):297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790","journal-title":"Br J Haematol"},{"key":"981_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16936","author":"J Dower","year":"2020","unstructured":"Dower J, Dima D, Sieker J, Pilichowska M, Varga C (2020) Eculizumab-induced late erythroid maturation arrest: a case report. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.16936","journal-title":"Br J Haematol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-00981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-00981-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-00981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:58Z","timestamp":1777564558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/2\/451\/8326102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-00981-8","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board at the Medical University of Vienna approved the study (identifier: 1368\/2014). Patients that were prospectively included in the study provided written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}